Efficient Scale-Up Of Genetically Modified MSCs In Multiplate Bioreactors

Hundreds of cell therapy products are in research and development (R&D) or pre-clinical phase worldwide. If the preclinical data of these products are promising, the developers face the challenge to optimize their small-scale processes to a scale which is sufficient for the treatment of one patient (autologous setting). At this stage, it is important to select an appropriate larger culture system that can achieve similar characteristics of the intended drug product as in the small-scale process. In addition, this culture system should also meet the clean room and GMP requirements.

This article focuses on the 2D scale-up of adherent cell cultures and provides guidance on how to efficiently achieve large-scale. Explore a case study where the data of an optimized multiplate bioreactor (MPB) process for the expansion of genetically modified mesenchymal stem cells (MSCs) is shown.